NeuTec Pharma Ltd.

NeuTec Pharma Ltd.

NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

Contact Details

Office Address

NeuTec Pharma Ltd.
Units 13, 15 and 18, Williams House, Manchester Science Park
Lloyd St. North, Manchester, UK M156SE
Phone: +44-161-276-8827
Fax: +44-161-276-8826

Executives

Chairman

Anthony F. (Tony) Martin

CEO

Prof James P. Burnie

Business Reviews for NeuTec Pharma Ltd.

Related Companies